Our Commitment
At the Thoracic Oncology Group of Australasia (TOGA), we are committed to improving lung cancer treatment and survival. Through the design of world-class research and trials, we hope to give you access to advanced treatment.
Support us
Inspire lung cancer patients through funding research and trials.
Impactful education
An education program to better equip you to implement new findings into your care.
Join us
Be part of TOGA and share a mission to prevent, treat, and cure thoracic cancer.
Research ideas
Our expert review process assists in developing high-quality funding applications.
Key Statistics About Thoracic Cancer
Every
0
minutes
a person living with lung cancer in Australia loses their life.
0
+
healthcare
professionals
empowered to integrate research findings into standard of care.
0
patients
were tested during the ASPiRATION trial, resulting in life-saving interventions.
Featured News
Consumer involvement can strengthen research design and grant applications. This practical guide explains when to involve consumers, what to ask, how to document their influence
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
